These preliminary findings suggest that combined treatment with MAAT and methylphenidate can improve attention, episodic and working memory, and executive functioning following traumatic brain injury.
The major issues of drug development are that pre-clinical animal efficacy studies do not accurately predict human efficacy, and clinical trials often inaccurately fail to show drug efficacy.
Sunovion have announced positive results from a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in adolescents aged 13 to 17 years old.
Connectivity in the right midfrontal gyrus may help predict placebo response. This finding has widespread implications in drug development.
There was a significantly greater improvement in memantine group and a greater response rate at weeks 4 and 6.
Medications used to treat addiction cut the risk of reoffending in half.
Researchers discovered novel opioid analgesics, displaying reduced respiratory depression.
The combination of behavioral and cognitive therapy approaches with medications is likely the most effective intervention for adults diagnosed with severe obsessive-compulsive disorder.
Neuroimaging studies have shown several neurophysiological substrates for depression: An overview by Theodore Henderson, MD, PhD.
Augmentation and combination approaches with pharmaceuticals are often used in clinical practice.
The FDA has mandated new warnings to include a list of compulsive behaviors.
American College of Physician researchers have released 2 recommendations for treatment of chronic insomnia disorder.
A chart outlining the pharmacokinetics of atypical antipsychotics, including information on bioavailability, half-life and CYP 450 metabolism.
Having more information on the long-term impact of antidepressants on weight could reduce the risk of weight-related morbidity for a large population of adults with depression.
No significant effect was found for preventing or treating delirium during hospitalization with antipsychotic medications.
The ACP recommends transparency in relation to pricing, costs, and comparative value.
Neither a specific antidepressant class nor individual drugs had any influence on the risk of stroke or transient ischemic attack over all of follow-up.
Treatment gives infusions of ketamine no more than once per week.
The number and timing of follow-up psychotherapy visits may be inadequate to deliver evidence-based psychotherapy.
No significant risks were found in adults; the risk of suicidality and aggression doubled in children and teens.
The bioequivalent of Adderall XR, the orally-disintegrating tablet Adzenys XR-ODT is an appealing option for treating ADHD in children.
Researchers found that 33.9% of the 1798 drug shortages were classified as within the scope of emergency medicine practice.
Probuphine works like a contraceptive implant, with 4 small implanted rods that provide a steady amount of medication for up to 6 months.
Results from a recent multiple sclerosis trial with simvastatin indicate that it could be an effective treatment to slow progression of Parkinson's.
The activation of a brain pathway mimicked an antidepressant-like response to ketamine in mice.
An abandoned drug for stroke treatment may provide a safer treatment than lithium in treating bipolar disorder.
Matching drugs to patients based on genetic profiles can optimize medication selection and help avoid adverse effects.
Teens who have been prescribed anxiety or sleep medications are more likely to abuse them than those without prescriptions.
Meta-analysis finds cognitive-behavioral therapy best type of psychotherapy in treating SAD, and more efficacious than using drugs.
Providers and patients may see better outcomes with simplified regimens.
Psychiatry Advisor Articles
- Low-Dose Dexmedetomidine Reduces Postoperative Delirium in Older Patients
- Lithium Side Effects for Bipolar Disorder Lead to Lower Prescription Rates
- First-Episode Schizophrenia Approaches Aided by Guidelines Instrument
- Predictors of Favorable Outcomes in First-Episode Psychosis Without Medication
- Patient Perception of Provider Engagement Impacts Progress